Khaoula Mazouzi: The Potential of Haemoglobin Vesicles as an Oxygen Carrier
Khaoula Mazouzi, Editorial Fellowship at Journal of Immunotherapy and Precision Oncology, shared a post on LinkedIn about a recent article by Kazuya Sakai et. al, published in BMJ Open, adding:
“What if blood could be manufactured in a lab!
Some scientific advances make you stop and rethink what could become possible in medicine.
This is one of them.
Researchers in Japan are developing haemoglobin vesicles: purified human haemoglobin encapsulated within liposomes, designed to carry oxygen as an alternative to red blood cell transfusion in emergencies.
The possibility of an oxygen carrier that does not require blood group matching is extraordinary, especially where compatible blood cannot reach a patient in time.
The 2026 BMJ Open publication describes a phase Ib protocol evaluating safety and pharmacokinetics at increasing doses in healthy volunteers.
It is an important step, with clinical efficacy still to be established.
But imagine the potential: severe haemorrhage, remote communities, disaster settings, and hospitals facing blood shortages.
Having practiced oncology in a resource-constrained setting, I find the question of access particularly powerful.
An innovation’s greatest value may be in the lives it could save where options are currently limited.
My first reaction was: this is mind-blowing.
If this technology ultimately delivers safe, effective, widely accessible oxygen support, I believe it could represent a Nobel Prize worthy achievement.
Deep respect to the researchers Kazuya Sakai and the team from Nara Medical University l whose persistence is bringing this possibility closer to patients.”
Title: Haemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative: an open-label, single-centre phase Ib study protocol in Japan
Authors: Kazuya Sakai, Kiyoshi Asada, Yudai Watanabe, Hiroshi Azuma, Hiromi Sakai, Masato Kasahara, Masanori Matsumoto

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series